WASF3 (Wiskott-Aldrich syndrome protein family member 3) is a cytoskeletal regulator critical for actin polymerization, cell migration, and cancer invasion. It interacts with the WASF regulatory complex (WRC), including CYFIP1, to modulate membrane protrusions and metastasis . Overexpression of WASF3 correlates with aggressive cancer phenotypes, including prostate, breast, and lung cancers .
This antibody enables precise detection of WASF3 in:
Immunofluorescence (IF): Tracking WASF3 localization in subcellular compartments (e.g., membrane protrusions, cytoplasm).
Western Blotting (WB): Quantifying WASF3 expression levels in lysates.
ELISA: Validating WASF3 protein presence in complex biological matrices .
Prostate Cancer: WASF3 knockdown reduces cell motility, invasion, and metastasis, with downregulated MMP-9 expression .
Breast Cancer: WASF3 depletion suppresses anchorage-independent growth and tumor formation in xenograft models .
Lung Cancer: Higher WASF3 expression in adenocarcinoma correlates with poor prognosis and advanced stages .
WASF3-CYFIP1 Interaction: Stapled peptides targeting this interface disrupt WASF3 activation, reducing Rac signaling and metastatic potential .
Small-Molecule Inhibitors: Compounds like N20 inhibit WASF3-mediated invasion without affecting viability, highlighting therapeutic potential .
The FITC-conjugated WASF3 antibody supports: